- Filed
- Feb 11, 2026
- Period
- FY2025
- Fiscal year end
- 12/31
- Filings
- 1
10-K · latest 10
What Bristol Myers Squibb's 10-K filings say
- SEC EDGAR
10-K · FY2025
Filed · Fiscal year ends 12/31 · 12 signals
BMY faces immediate revenue cliff as Revlimid and Pomalyst lose exclusivity in Q1 2026
Full generic competition for blockbuster drug Revlimid began on Jan 31, 2026, and generic entry for Pomalyst is expected in Q1 2026.
Pomalyst faces US generic entry in Q1 2026, creating imminent revenue pressure.
The imminent loss of market exclusivity for Pomalyst in the US will directly impact a key revenue stream starting in the first quarter of 2026.
Revlimid loses volume-limited protection against generics on January 31, 2026.
As of January 31, 2026, licensing agreements for generic versions of the blockbuster drug Revlimid will no longer be volume-limited.
Blockbuster drug Eliquis faces US generic launch in 2028 and active EU competition.
Bristol-Myers Squibb faces a major patent cliff with its key product Eliquis, with settled generic entry permitted in the US in 2028 and generic versions already being marketed in some EU countries.
Pfizer
Revlimid faces unlimited generic competition in the US starting January 31, 2026
Previously volume-limited licenses for generic versions of Revlimid will become unlimited after January 31, 2026.
Generics erode Eliquis sales in the EU; US market faces patent cliff in 2028
Generic versions of the major drug Eliquis are already being marketed in some EU countries, impacting current international revenue.
Pfizer
BMY pivots R&D to novel modalities like cell therapy, ADCs, and radiopharmaceuticals
The company is concentrating its R&D efforts in high-unmet-need areas like oncology and immunology, utilizing advanced, data-intensive platforms such as cell therapies, protein degraders, and radiopharmaceuticals.
cell therapiesprotein degradersADCsradiopharmaceuticals
Generic entry for Pomalyst is expected in the US in Q1 2026
The company anticipates losing market exclusivity for its drug Pomalyst in the U.S.
Actively litigating against generic manufacturers to defend key product patents
Bristol-Myers Squibb is engaged in ongoing, costly patent litigation against multiple generic companies challenging its key products.
Pfizer
Multiple key products including Abraxane and Sprycel have already lost exclusivity
Generics have already entered the market for former key products Abraxane and Sprycel in the U.S., EU, and Japan.
Showing 10 of 12 filing signals. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Bristol Myers Squibb with the Signal API
One POST /v1/companies/enrich call with bms.com returns Bristol Myers Squibb 10-K signals (sec-10k), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"bms.com","signal_types":["sec-10k"],"limit":20}'Same industry
10-K at related companies
Questions about Bristol Myers Squibb 10-K
When did Bristol Myers Squibb file its latest 10-K?
What does Bristol Myers Squibb's latest 10-K say about restructuring?
Where can I find Bristol Myers Squibb's annual report?
Source. Annual reports (Form 10-K) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .